新天药业
(002873)
| 流通市值：23.54亿 | | | 总市值：23.97亿 |
| 流通股本：2.40亿 | | | 总股本：2.44亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 167,125,200.8 | 173,719,574.8 | 169,425,275.78 | 94,467,566.35 |
| 交易性金融资产 | 89,770.86 | 96,871.38 | 102,450.36 | 95,857.02 |
| 应收票据及应收账款 | 264,113,397.53 | 281,631,549.34 | 262,174,309.67 | 284,243,877.08 |
| 其中：应收票据 | 9,527,218.82 | 13,230,560.29 | 9,586,086.57 | 7,837,288.24 |
| 应收账款 | 254,586,178.71 | 268,400,989.05 | 252,588,223.1 | 276,406,588.84 |
| 应收款项融资 | 1,746,680.47 | 5,211,004.31 | 1,677,755.48 | 6,329,306.3 |
| 预付款项 | 4,646,804.14 | 3,251,410.05 | 12,519,573.66 | 8,100,205.84 |
| 其他应收款合计 | 10,535,119.19 | 8,126,668.35 | 24,097,789.27 | 16,576,671.12 |
| 存货 | 159,990,812.42 | 172,114,277.97 | 180,452,213.23 | 146,199,483.75 |
| 其他流动资产 | 5,881,704.74 | 6,883,680.36 | 3,380,185.1 | 3,984,821.85 |
| 流动资产合计 | 614,129,490.15 | 651,035,036.56 | 653,829,552.55 | 559,997,789.31 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 530,322,225 | 530,322,225 | 530,322,225 | 412,045,700 |
| 其他非流动金融资产 | 22,344.2 | 22,344.2 | 22,601.7 | 22,601.7 |
| 投资性房地产 | 6,553,951.95 | 6,042,719.37 | 4,950,606.52 | 4,364,152.04 |
| 固定资产 | 611,160,696.8 | 617,860,236.41 | 622,210,487.05 | 628,841,022.29 |
| 在建工程 | 77,613,285.04 | 65,917,325.76 | 53,809,200.67 | 53,138,091.6 |
| 使用权资产 | 8,410,342.59 | 9,603,552.26 | 10,384,248.23 | 11,301,709.66 |
| 无形资产 | 106,984,093.91 | 108,617,663.74 | 108,325,543.57 | 106,663,136.44 |
| 开发支出 | 97,742,019.46 | 92,430,172.81 | 89,980,870.81 | 87,751,035 |
| 商誉 | 6,185,055.14 | 6,185,055.14 | - | - |
| 长期待摊费用 | 8,932,253.73 | 9,680,789.84 | 8,442,094.8 | 9,557,320.12 |
| 递延所得税资产 | 8,565,236.48 | 9,034,168.83 | 10,655,924.49 | 10,297,126.76 |
| 其他非流动资产 | 15,158,565.11 | 14,323,017.93 | - | - |
| 非流动资产合计 | 1,477,650,069.41 | 1,470,039,271.29 | 1,439,103,802.84 | 1,323,981,895.61 |
| 资产总计 | 2,091,779,559.56 | 2,121,074,307.85 | 2,092,933,355.39 | 1,883,979,684.92 |
| 流动负债: | | | | |
| 短期借款 | 85,027,500 | 95,878,471.36 | 59,018,276.25 | 71,063,276.26 |
| 应付票据及应付账款 | 56,241,978.96 | 68,585,313.44 | 106,889,973.08 | 82,295,885.11 |
| 应付账款 | 56,241,978.96 | 68,585,313.44 | 106,889,973.08 | 82,295,885.11 |
| 预收款项 | 68,323.36 | 81,950.71 | 4,586.84 | 66,165.41 |
| 合同负债 | 466,856.11 | 366,620.16 | 664,141.29 | 438,271.04 |
| 应付职工薪酬 | 30,214,996.82 | 29,705,470.39 | 22,879,282.98 | 13,752,141.23 |
| 应交税费 | 19,548,410.58 | 13,654,842.2 | 16,615,820.9 | 14,375,655.81 |
| 其他应付款合计 | 33,977,818.72 | 22,795,577.24 | 19,989,040.15 | 16,723,913.28 |
| 一年内到期的非流动负债 | 230,909,899.33 | 146,774,259.25 | 73,538,964.11 | 10,934,705.34 |
| 其他流动负债 | 771,021.2 | 2,352,755.18 | 2,163,934.39 | 1,520,381.27 |
| 流动负债合计 | 457,226,805.08 | 380,195,259.93 | 301,764,019.99 | 211,170,394.75 |
| 非流动负债: | | | | |
| 长期借款 | 311,962,500 | 420,770,000 | 463,240,000 | 432,950,000 |
| 租赁负债 | 4,439,898.26 | 5,479,045.84 | 6,147,811.99 | 7,140,300.1 |
| 长期应付款 | 501,541.22 | 524,767.22 | 528,409.22 | 531,811.22 |
| 递延收益 | 24,369,682.72 | 24,265,969.95 | 24,121,284.55 | 23,766,265.94 |
| 递延所得税负债 | 33,539,455.96 | 33,594,761.71 | 33,817,862.08 | 22,056,853.42 |
| 非流动负债合计 | 374,813,078.16 | 484,634,544.72 | 527,855,367.84 | 486,445,230.68 |
| 负债合计 | 832,039,883.24 | 864,829,804.65 | 829,619,387.83 | 697,615,625.43 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 244,103,806 | 244,103,806 | 244,103,806 | 244,103,806 |
| 资本公积 | 282,352,942.7 | 282,352,942.7 | 282,352,942.7 | 282,352,942.7 |
| 减:库存股 | 75,303,968.97 | 75,303,968.97 | 75,303,968.97 | 75,303,968.97 |
| 其他综合收益 | 144,773,891.25 | 144,773,891.25 | 144,773,891.25 | 78,238,845 |
| 盈余公积 | 104,332,585.05 | 104,332,585.05 | 101,927,921.67 | 101,927,921.67 |
| 未分配利润 | 559,480,420.29 | 555,985,247.17 | 565,459,374.91 | 555,044,513.09 |
| 归属于母公司股东权益合计 | 1,259,739,676.32 | 1,256,244,503.2 | 1,263,313,967.56 | 1,186,364,059.49 |
| 股东权益合计 | 1,259,739,676.32 | 1,256,244,503.2 | 1,263,313,967.56 | 1,186,364,059.49 |
| 负债和股东权益合计 | 2,091,779,559.56 | 2,121,074,307.85 | 2,092,933,355.39 | 1,883,979,684.92 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-07-31 |
| 审计意见(境内) | | 标准无保留意见 | | |